Seeing the Unseen for 25 Years

For 25 years, Alexion has seen opportunities where others have not. We have had the courage to explore what others believe is impossible. And we have forged a pathway from innovative science to breakthrough therapies for patients suffering from devastating diseases that had previously been overlooked. Learn more.

From Our Leadership

As we fulfil our mission of serving patients with severe and life-threatening rare diseases, Alexion has built its European presence to meet the needs of patients locally. Today, our European operations serve patients in more than 30 countries. In addition, several of Alexion’s key global functions are based in Europe, including our EMEA headquarters in Switzerland and our global supply chain and quality operations in Ireland. We also have a global government affairs team in Brussels, a research and development centre in Paris, and country operations throughout the region. Alexion’s talented and driven employees are dedicated to providing life-transforming treatments to patients with severe and life-threatening rare diseases for which there are few, if any, effective treatment options. We invite you to learn more about what we do.

— Christophe Bourdon
Senior Vice President, EMEA

 

HIGHLIGHTS

 

European Commission Approves Soliris for Patients with Refractory gMG

The European Commission has approved the extension of the indication for Soliris® (eculizumab) to include the treatment of refractory generalized myasthenia gravis (gMG) in adults who are anti-acetylcholine receptor (AChR) antibody-positive. Soliris is the first and only complement-based therapy approved in the European Union for this ultra-rare subset of MG patients. Read the press release for more information.

 

Alexion Receives International Investor Award 2016

Alexion is honored to have received a 2016 International Investor Award from the Greater Paris Investment Agency (Paris-Ile de France Capitale Economique) for its significant investment and growth in Paris, France. Alexion first established its presence in France in 2005 and, in 2015, opened a new Research and Development Center in Paris – its first European research hub for rare and severe diseases. Alexion’s R&D Center Paris, which is located at the campus of the Necker Hospital at the Imagine Institute, focuses on discovery research activities in the fields of cell and molecular biology, genomics, and immunogenicity. Read the press release and learn more about Alexion’s R&D Center.

 

Alexion Announces Additional Investment in Ireland

Alexion has announced an additional €100 million investment in its Athlone operations in Ireland, which will result in the creation of 50 additional jobs. The investment will see the construction of a new biologics manufacturing facility at the site. Read the media statement.



 

CONTACT

EMEA Headquarters
Alexion Pharma GmbH


Giessh├╝belstrasse 30
8045 Z├╝rich, Switzerland
  • +41 44  457 40 00
  • +41 44 457 40 01